The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 28, No. 11, pp. 1236-1238.
© 1994 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carlson, J.
Right arrow Articles by Maesner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carlson, J.
Right arrow Articles by Maesner, J.

Research Articles

Fatal neutropenia and thrombocytopenia associated with ticlopidine

JA Carlson and JE Maesner

OBJECTIVE: To report the first case of ticlopidine-associated neutropenia resulting in sepsis and death. CASE SUMMARY: An 83-year-old Filipino man was started on ticlopidine 250 mg bid. By the seventh week of therapy his absolute neutrophil count (ANC) had dropped to 2700 from 7600 x 10(6) cells/L. The ticlopidine was stopped. Six days later, he was admitted to the hospital. He died 18 hours later of gram-negative sepsis. DISCUSSION: Although ticlopidine therapy was discontinued four days after the patient's ANC was 2700 x 10(6) cells/L, the ANC dropped to and remained at 0 until his death eight days later. This may be associated with the patient's decreased clearance of ticlopidine given his age and impaired renal function. This is the first reported case of moderate or severe neutropenia in a nonwhite patient and the first reported case of sepsis and death caused by ticlopidine. CONCLUSIONS: Healthcare professionals must be aware of the possibility of severe neutropenia and death caused by ticlopidine, even when the manufacturers' monitoring guidelines are followed.


This article has been cited by other articles:


Home page
 Vasc MedHome page
G. Agnelli
Rationale for the use of platelet aggregation inhibitors in PAD patients
Vascular Medicine, February 1, 2001; 6(1_suppl): 13 - 15.
[Abstract] [PDF]

Home page
 CMAJHome page
F. L. Paradiso-Hardy, C. M. Angelo, K. L. Lanctot, and E. A. Cohen
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality
Can. Med. Assoc. J., November 1, 2000; 163(11): 1441 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Urban, C. Macaya, H.-J. Rupprecht, F. Kiemeneij, H. Emanuelsson, A. Fontanelli, M. Pieper, T. Wesseling, L. Sagnard, and f. t. M. Investigators
Randomized Evaluation of Anticoagulation Versus Antiplatelet Therapy After Coronary Stent Implantation in High-Risk Patients : The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS)
Circulation, November 17, 1998; 98(20): 2126 - 2132.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. R. Makkar, F. Litvack, N. L. Eigler, M. Nakamura, P. A. Ivey, J. S. Forrester, P. K. Shah, R. E. Jordan, and S. Kaul
Effects of GP IIb/IIIa Receptor Monoclonal Antibody (7E3), Heparin, and Aspirin in an Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis
Circulation, February 18, 1997; 95(4): 1015 - 1021.
[Abstract] [Full Text]


homecopy help contact us subscription past issues search current issue
Copyright © 1994 by Harvey Whitney Books Company.